Head-to-head · WeighScore
Ilant Health vs Options Medical Weight Loss
The verdict
Options Medical Weight Loss takes it — 65.5/100 to 56.8/100.
Options Medical Weight Loss grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Options Medical Weight Loss offers telehealth medical weight-loss programs built around compounded GLP-1 — semaglutide starting around $239/month and tirzepatide from $299/month, plus NAD+ injections at…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ilant Health | Options Medical Weight Loss |
|---|---|---|
| WeighScore | 56.8/100 | 65.5/100 |
| Grade | C | C |
| Scorecard rank | #407 | #218 |
| Semaglutide | Not disclosed | $199/mo (compounded) |
| Tirzepatide | Not disclosed | $399/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #407 · C
Strengths
- Value-based, outcomes-driven obesity care model
- Includes GLP-1 medications with transparent drug pricing for sponsors
- Care team of board-certified obesity providers and behavioral specialists
- Dietitians and peer navigators support adherence
- Data-driven stratification targets the right interventions
Where it loses points
- Distributed via employers and health plans, not direct cash-pay
- Individuals generally cannot enroll without sponsor coverage
- No public consumer pricing for GLP-1
- Access gated behind organizational buyers
- Not suited to consumers wanting direct-to-door GLP-1
Graded #218 · C
Strengths
- LegitScript certified with clear, upfront program pricing
- Compounded semaglutide (~$239) and tirzepatide (from $299), plus NAD+
- Structured metabolic-health program with provider support and accountability
- HSA/FSA eligible with flexible payment options
Where it loses points
- Doesn't clearly publish which states its telehealth covers
- Tirzepatide tiers climb to $339-$399/month
- More program structure (and cost) than medication-only sellers
- Compounded GLP-1 only online — no brand-name options noted
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.